US Bancorp DE Sells 30,755 Shares of AbbVie Inc. $ABBV

US Bancorp DE trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 1.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,400,194 shares of the company’s stock after selling 30,755 shares during the quarter. US Bancorp DE owned 0.14% of AbbVie worth $555,743,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after buying an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares during the period. Schnieders Capital Management LLC. lifted its position in shares of AbbVie by 5.0% during the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares during the last quarter. Advisory Alpha LLC boosted its stake in shares of AbbVie by 13.9% during the second quarter. Advisory Alpha LLC now owns 5,731 shares of the company’s stock valued at $1,064,000 after purchasing an additional 701 shares during the period. Finally, Austin Private Wealth LLC grew its holdings in shares of AbbVie by 13.9% in the second quarter. Austin Private Wealth LLC now owns 4,781 shares of the company’s stock worth $887,000 after purchasing an additional 585 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on ABBV. Evercore lowered their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. UBS Group lowered their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. Royal Bank Of Canada initiated coverage on AbbVie in a research note on Tuesday. They issued an “outperform” rating and a $260.00 price objective on the stock. Barclays began coverage on AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price for the company. Finally, Raymond James Financial set a $256.00 price target on AbbVie in a research report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Stock Down 0.6%

Shares of ABBV opened at $227.01 on Thursday. The company has a 50 day moving average of $224.22 and a two-hundred day moving average of $222.70. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company has a market cap of $401.38 billion, a price-to-earnings ratio of 96.19, a price-to-earnings-growth ratio of 0.79 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.